Please login to the form below

Not currently logged in
Email:
Password:

Pfizer and Mylan to market generic drugs in Japan

Will collaborate on portfolio of more than 350 existing products in expanding market

Pfizer and Mylan are to work together to develop, manufacture and market a range of generic drugs in Japan under the Pfizer brand.

The deal will involve a combined portfolio of more than 350 products across a range of therapeutic categories, as well as more than 125 additional products in development.

As part of the agreement, US-based generic firm Mylan will have responsibility for managing operations, including R&D and manufacturing, while Pfizer will handle commercialisation efforts and managing a combined sales and marketing team.

The companies will share costs and profits resulting from the collaboration, although specific terms are confidential. Both Mylan and Pfizer will also continue to operate independently in Japan.

The companies will also be looking to capitalise on a growing generics market in Japan, currently the sixth largest in the world and worth $5.2bn last year. The market is also poised for further growth, with the Japanese government aiming to increase the current volume of generic use from 24 per cent to 30 per cent by the end of 2012.

Further growth drivers for Japan's generics market will come from its aging population, patent expiries for major drugs and attempts to reduce healthcare spending.

This is in line with an expansion of the global generic drug market, which is due to increase in annual worth from $124bn in 2010 to $231bn by 2017.

Confirming these expectations Mylan's CEO Heather Bresch said: "We are very excited to have the opportunity to be partnering with Pfizer to build upon our existing assets and drive an even stronger, more sustainable generics business in Japan - one which will be well-positioned to take advantage of anticipated growth in generic utilisation in this market and other significant growth opportunities.”

23rd August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Marketing Tree
Channeling your inner disrupter
Channel strategy has long been a hot topic for pharma and is often regarded as the answer to many of today's marketing challenges...
Influencing behaviour change: Looking beyond market research
These strategies will give you the insight you need to influence behaviour change by creating a meaningful pharma customer journey....
Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...

Infographics